Stockreport

Allena Pharmaceuticals Initiates First Phase 3 Trial for ALLN-177 in Patients with Enteric Hyperoxaluria

Allena Pharmaceuticals, Inc.  (ALNA) 
Last allena pharmaceuticals, inc. earnings: 3/16 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.allenapharma.com/investor-relations
PDF URIROX-1TM is the Largest Controlled Trial of a Novel Therapeutic for this Underserved Patient Population -  Topline Data Expected in Second Half of 2019  -ALLN-177 has [Read more]